

Interim Results for the Period Ending 31st January 2019

April 9th, 2019

Affimer®

No representation or warranty, expressed or implied, is made or given by or on behalf of Avacta Group plc (the "Company" and, together with its subsidiaries and subsidiary undertakings, the "Group") or any of its directors or any other person as to the accuracy, completeness or fairness of the information contained in this presentation and no responsibility or liability is accepted for any such information. This presentation does not constitute an offer of securities by the Company and no investment decision or transaction in the securities of the Company should be made solely on the basis of the information contained in this presentation.

This presentation contains certain information which the Company's management believes is required to understand the performance of the Group. However, not all of the information in this presentation has been audited. Further, this presentation includes or implies statements or information that are, or may deemed to be, "forward-looking statements". These forward-looking statements may use forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will" or "should". By their nature, forward-looking statements involve risks and uncertainties and recipients are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's or the Group's actual results and performance may differ materially from the impression created by the forward-looking statements or any other information.

The Company undertakes no obligation to update or revise any information contained in this presentation, except as may be required by applicable law or regulation. Nothing in this presentation is intended to be, or intended to be construed as, a profit forecast or a guide as to the performance, financial or otherwise, of the Company or the Group whether in the current or any future financial year.

This presentation and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person.

Certain information in this presentation has been extracted from announcements made by the Company and this presentation is not a substitute for reading the Company's announcements in full.



Operational Highlights for the Period Ended 31st January 2019

Affimer®

Affimer Therapeutics

- Major development partnership and license agreement with LG Chem Life Sciences (LG Chem) potentially worth over \$300m plus future royalties on product sales. The agreement included an upfront payment of \$2.5m, near-term milestone payments of up to a further \$5.5m plus payment of Avacta's research costs.
- Continuing to build the in-vivo pharmacology data packages for our lead immune checkpoint programmes.
- Research collaboration and licensing agreement, to access novel drug conjugate technology developed at Tufts University Medical School, established to underpin pipeline of innovative "TMAC" Affimer drug conjugates and combination therapies.



Operational Highlights for the Period Ended 31st January 2019

Affimer®

Affimer Research and Diagnostics Reagents

- Custom Affimer sales pipeline largest value to date including multiple global *in vitro* diagnostic companies, pharma and biotech companies and bioprocessing companies
- Agreed commercial license with New England Biolabs[®] (NEB[®]), a global leader in the discovery and production of enzymes for molecular biology applications. This agreement is to commercialise a product using the Affimer technology for use in both life science research and diagnostics assays.
- Strong focus on generating further license deals during 2019 arising from multiple ongoing technology evaluations.
- Good progress in building a proprietary pipeline of Affimer reagents against specific diagnostic targets with the aim of generating two diagnostic assets with the supporting data packages during 2019 for future licensing.



Financial Highlights for the Period Ended 31st January 2019

Affimer

Financial highlights

- First up-front milestone payment of \$2.5m received from LG Chem.
- Fund raising completed August 2018, with £11.6m gross received.
- Cash balances £11.8m (£5.2m 31 July 2018).
- Half year revenues of £1.0m (£1.5m FY18) reduced due to absence of services revenue for FTEs working on the Moderna collaboration now that assets have been transferred into their development pipeline. LG Chem funded research services commenced February 2019 and will contribute to second half-year figures.
- Operating loss £5.9m (£4.5m FY18), with research and development costs increasing to £2.4m (£1.5m FY18).
- Increased R&D costs leading to reported loss of £5.2m (£3.9m FY18).

Senior Management

• Dr Jose Saro appointed in December 2018 as Chief Medical Officer to lead the preclinical and clinical development of the Affimer[®] therapeutic platform. Dr Saro joined Avacta from Roche where he held the role of Senior Translational Medicine Leader at the Roche Innovation Center Zurich.



Interim Results for the Period Ending 31st January 2019: Income Statement

Affimer

	Unaudited 6 months 31 Jan 2019 (£m)	Unaudited 6 months 31 Jan 2018 (£m)	Audited Year ended 31 July 2018 (£m)
Revenue	0.97	1.47	2.76
Life Sciences	0.29	0.69	1.19
Animal Health	0.68	0.77	1.57
Gross profit	0.66	1.01	1.87
Gross margin	68%	69%	68%
R&D costs	(2.41)	(1.48)	(3.78)
Administrative costs	(4.12)	(4.00)	(8.52)
Operating loss	(5.87)	(4.47)	(10.43)
Taxation	0.65	0.50	1.56
Retained loss	(5.20)	(3.95)	(8.83)
Loss per share	4.80p	6.04p	13.49p



Interim Results for the Period Ending 31st January 2019: Cash Flow and Balance Sheet

Affimer®

	Unaudited 6 months 31 Jan 2019 (£m)	Unaudited 6 months 31 Jan 2018 (£m)	Audited Year ended 31 July 2018 (£m)
Operating activities	(2.90)	(3.59)	(5.47)
Capex – PPE & Development	(1.42)	(1.34)	(2.52)
Financing	10.89	0.04	0.04
Net cash flow	6.57	(4.89)	(7.95)
Cash & Deposits	11.79	8.28	5.22
PPE	2.91	3.39	3.05
Intangible assets	12.71	12.78	12.20
Other net assets/(liabilities)	(0.08)	1.73	0.94
Net assets	27.33	26.18	21.41






Business Update

Partnership with LG Chem Life Sciences

Affimer®

From the LG Chem presentation at the JP Morgan Healthcare conference January 2019






Collaboration and License Deal to Access IP from Tufts University

Affimer

- The TMAC[™] drug conjugate concept is a joint invention between Avacta and Tufts University School of Medicine.
- Avacta has agreed a co-development partnership with Bach BioSciences, a company commercialising the research of William Bachovchin, Professor of Developmental, Chemical and Molecular Biology at Tufts University School of Medicine, Boston.
- Avacta and Tufts have jointly filed a patent application to protect the concept of a tumour microenvironment activated drug conjugate immunotherapy (TMACTM).
- The license agreement provides Avacta with exclusive access to the FAP enzyme activated linker chemistry and certain chemo-toxin warheads developed by Professor Bachovchin.
- Avacta has sole commercial rights to the TMAC platform and the agreement provides for a royalty payment to Bach/Tufts.



Patent Application July 2018: *Tumor Microenvironment – Activated Drug-Binder Conjugates, and Uses Related Thereto.* US Patent Application Serial Number 62/680,300





Moderna Exercises its Option to Develop and Commercialise Certain Affimers

- Multi-target deal (May 2015) to co-develop Affimer therapeutics for undisclosed indications.
- Upfront, near-term and clinical development milestones worth up to "tens of millions of dollars".
- Royalties on future sales plus full funding of Avacta's associated R&D costs.
- Avacta has generated a number of Affimer lead molecules against multiple targets nominated by Moderna.
- Moderna has exercised its option to take one or more of the lead molecules into clinical development (February 2019).


moderna

Affimer



Affimer

Avacta's mission is to extend the benefit of cancer immunotherapies with innovative and differentiated Affimer therapeutics combining modulation of multiple checkpoints with pro-inflammatory drugs




Only ~20% of patients respond to current immuno-modulatory monotherapies*

* Levitsky, SITC 2014




Affimer

Novel tumour microenvironment active drug conjugates (TMAC[™]) and combination therapies built around PD-L1 multi-specifics




70% patients

Key Benefits: Formatting flexibility, small size, proprietary TMAC concept, proprietary pro-drugs




Inflamed Tumours Strategy: Multi-specific Therapies



30% patients

Key Benefits: Formatting flexibility, small size, solubility, stability





The Broader Affimer TMAC[™] Platform Opportunity

Affimer®


First TMAC Programme

 $\text{FAP}\alpha$ sensitive linker



I-DASH inhibitor warhead

Broad TMAC patent covers a range of I-O targeting, linkers and warheads and Avacta owns all the commercial rights to the TMAC platform



Immuno-oncology Active Targeting

Induction/maintenance of adaptive immune response overcoming immune evasion.

- PD-L1, other immunecheckpoints, bispecifics and costimulatory receptors
- Additional tumour targeting via tumour specific biomarker if required

Tumour Microenvironment Sensitive Linkers

Tumour microenvironment enzyme sensitive linkers provide secondary targeting mechanism.

- FAP α
- MMP2, MMP9, MMP14
- Matriptase
- Legumain



Synergistic Toxins

I-O Active warheads **targeting "bystander" cells**, including macrophage, NK cells, etc. and supporting tumor stroma.

- DPP8/9; proteasome; AKT; CDK inhibitors
- STING; TLR7/8 agonists
- Doxorubicin

Patent Application July 2018: Tumor Microenvironment - Activated Drug-Binder Conjugates, and Uses Related Thereto. US Patent Application Serial Number 62/680,300



Pipeline: Principal In-house Programmes


Affimer

Programme	Discovery	Lead Optimisation	Pre-clinical	Phase 1
Checkpoint Antagonist	S			
AVA004 PD-L1	X			
AVA017 LAG-3		AVA-021 Bispecif	ic	
Costimulatory Agonists	5			
AVA026 4-1BB				
AVA023 CD40				
Affimer TMAC [™] Drug C	onjugates			
AVA004-100 PD-L1/I-D	ASH			School of Medicine
Technology Developme	ent			
AVA003 Affimer XT (se	rum albumin)			
Undisclosed PK/ADME	Modifiers			🕒 LG Chem



Key Preclinical and Clinical Milestones

Affimer®





Appointment of Dr Jose Saro as Chief Medical Officer

Affimer®



Dr Jose Saro

- Over 20 years' experience in the pre-clinical, translational and early clinical development of oncology assets.
- Joined Avacta from Roche where he held the role of Senior Translational Medicine Leader at the Roche Innovation Center Zurich in which he focused on immuno-oncology and the development of combination products.
- Prior to his position at Roche, Dr Saro was Executive Director Oncology Global Development and Medical Affairs at Bristol Myers Squibb, based in Paris, where he led and contributed to many oncology clinical development programmes, including Sprycel, Ipilimumab (Yervoy anti-CTLA4), Nivolumab (anti-PD1), anti-PDL1, anti KIR, anti LAG3, Brivanib, MEK inhibitor and Elotuzumab.
- Previously, Dr Saro was Executive Director of Translational Medicine and Early Clinical Development (Oncology) at Novartis, and has held senior positions at Eisai, and Wyeth.




Affimer®

Differentiated Affimer reagents for research and diagnostics markets

- Building a profitable reagents business as quickly as possible by supplying or licensing Affimers into high value applications in diagnostics and research.
- Focus is on applications and/or targets where Affimers present a significant advantage over established antibody-based techniques.
- Balance short-term revenue potential


 fee for service, and longer-term
 higher value revenue stream –
 milestones and royalties.





Affimer Reagents: Business Update

Affimer





Affimer Reagents: 2019 Targets

Affimer®

- Total Affimer services revenue £1.5m(E) (£1.2m 2018).
- Secure further reagents license deals through technology evaluations to underpin long term royalties.
- Develop at least one diagnostic immuno-assay product for licensing:
 - Quicker route to licensing deals than relying on third parties to evaluate the technology and develop the diagnostic test before licensing.
 - Currently generating Affimers for several diagnostics targets for which there is unmet need, or current tests perform poorly, or there is commercial opportunity in emerging markets.
 - One or more of these will be developed into diagnostic immunoassays with the aim of demonstrating differentiated performance over currently available tests during 2019.

JF	
7	



Summary

Affimer



Best-in-class antibody alternative technology

The Affimer platform is a best-in-class antibody alternative with superior formatting flexibility coupled with high expression levels, stability and solubility.

Therapeutics strategy focused on extending the benefit of immunotherapies



Proprietary pipeline of **multi-specifics** and **novel TME active drug conjugates (TMAC[™])** to extend the benefit of immunotherapies to a much wider group of patients.



Considerable uplift opportunity

Significant commercial, pre-clinical and clinical milestones should be achieved in the **near future** that would support **considerable valuation uplift**.

Highly disruptive



Affimer® technology is not based on antibodies so it is not covered by antibody IP and therefore gives new entrants an opportunity to compete in valuable markets.



Affimer is a **platform technology** capable of generating a continuous pipeline of products. Unlike classic biotech companies, Avacta has **downside protection** for investors from a reagents business

Downside risk protection through revenue generating reagents business

Avacta

finnCap Ltd (Broker and Nomad) Geoff Nash / Giles Rolls – Nominated Advisors Tim Redfern / Alice Lane – Corporate Broking www.finncap.com T +44 (0) 207 220 0500

WG Partners (Broker) Nigel Birks / Nigel Barnes Andrew Craig/ Claes Spang T +44 (0) 203 705 9318 www.wgpartners.co.uk Yellow Jersey PR Sarah Hollins / Harriet Jackson avacta@yellowjerseypr.com www.yellowjerseypr.com M +44 (0)7764 947 137

Zyme Communications (Trade and Regional Media) Katie Odgaard T +44 (0) 203 727 1000 <u>katie.odgaard@zymecommunications.com</u>